Table 2.
Clinicopathologic characteristics of P-NET patients in the SEER cohort and validation cohort
| Parameter | SEER cohort (N=2174) | Validation cohort (N=81) |
|---|---|---|
| N (%) | N (%) | |
| Age, years | ||
| ≤60 | 1218 (56) | 63 (78) |
| >60 | 956 (44) | 18 (22) |
| Sex | ||
| Male | 1154 (53) | 49 (60) |
| Female | 1020 (47) | 32 (40) |
| Race | ||
| Caucasian | 1741 (80) | 0 |
| Black | 229 (11) | 0 |
| Other and Unknown | 204 (9.4) | 81 (100) |
| Location | ||
| Head | 692 (32) | 32 (40) |
| Body and Tail | 1103 (51) | 44 (54) |
| Other | 379 (17) | 5 (6) |
| Histologic grade* | ||
| I | 1552 (71) | 37 (46) |
| II | 427 (20) | 31 (38) |
| III or IV | 195 (9.0) | 13 (16) |
| WHO grade | ||
| I | - | 45 (56) |
| II | - | 27 (33) |
| III | - | 9 (11) |
| Stage (AJCC 7th edition) | ||
| I | 976 (45) | 47 (58) |
| II | 810 (37) | 27 (33) |
| III | 45 (2.1) | 1 (1) |
| IV | 343 (16) | 6 (7) |
| Stage (ENETS) | ||
| I | 446 (21) | — |
| II | 569 (26) | — |
| III | 816 (38) | — |
| IV | 343 (16) | — |
| Size (mm) | ||
| <34.5 | 1178 (54) | 49 (60) |
| >34.5 | 996 (46) | 32 (40) |
| LNR | ||
| 0 | 1343 (62) | 73 (90) |
| <0.33 | 475 (22) | 2 (3) |
| >0.33 | 356 (16) | 6 (7) |
| Functional status | ||
| Functional | 278 (13) | 34 (42) |
| Nonfunctional | 1896 (87) | 47 (58) |
Notes: *Histologic grade assessed by tissue differentiation based on HE staining. Abbreviations: AJCC, American Joint Committee on Cancer; ENETS, European Neuroendocrine Tumor Society.